Alumis (NASDAQ:ALMS) Insider Sanam Pangali Sells 1,364 Shares of Stock

Alumis Inc. (NASDAQ:ALMS) insider Sanam Pangali sold 1,364 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $35,968.68. Following the sale, the insider directly owned 9,747 shares of the company’s stock, valued at approximately $257,028.39. This trade represents a 12.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Sanam Pangali also recently made the following trade(s):

• On Monday, July 6th, Sanam Pangali sold 5,000 shares of Alumis stock. The stock was sold at an average price of $28.00, for a total transaction of $140,000.00.

Alumis Price Performance

ALMS opened at $27.12 on Thursday. The business has a fifty day simple moving average of $25.37 and a 200-day simple moving average of $25.22. Alumis Inc. has a 52 week low of $3.76 and a 52 week high of $31.35. The firm has a market cap of $3.46 billion, a P/E ratio of -13.70 and a beta of -0.69.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The business had revenue of $1.74 million during the quarter, compared to analyst estimates of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. Sell-side analysts expect that Alumis Inc. will post -2.87 earnings per share for the current year.

Alumis News Summary

Here are the key news stories impacting Alumis this week:

• Neutral Sentiment: HC Wainwright reaffirmed its “Neutral” rating on Alumis, indicating the analyst does not currently see a strong enough catalyst to support a more bullish view. HC Wainwright Reaffirms Neutral Rating for Alumis
• Negative Sentiment: Six company insiders, including CFO John R. Schroer, sold a combined 14,953 shares of Alumis on August 3 at an average price of $26.37, generating approximately $394,311 in proceeds. The sales reduced individual holdings by roughly 1.28% to 12.28%; the CFO’s position declined 11.72%. While insider sales can reflect personal financial planning rather than a change in business outlook, the concentration of sales may weigh on investor sentiment. The transactions were reported in SEC filings for Read More., Read More., Read More., Read More., Read More., and Read More..

Analyst Upgrades and Downgrades

Several research firms recently commented on ALMS. Wall Street Zen cut Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Chardan Capital upped their target price on shares of Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, May 19th. Wells Fargo & Company raised their target price on shares of Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a report on Tuesday, July 7th. Finally, HC Wainwright reiterated a “neutral” rating and set a $25.00 target price on shares of Alumis in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $40.30.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ALMS. Samsara Biocapital LLC raised its stake in Alumis by 19.9% during the 4th quarter. Samsara Biocapital LLC now owns 5,756,984 shares of the company’s stock worth $56,188,000 after acquiring an additional 955,614 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Alumis by 18.4% during the third quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock worth $16,078,000 after acquiring an additional 625,404 shares during the last quarter. Cormorant Asset Management LP increased its holdings in shares of Alumis by 69.3% in the 4th quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock valued at $35,483,000 after acquiring an additional 1,488,200 shares during the period. Octagon Capital Advisors LP grew its position in Alumis by 11.9% during the 1st quarter. Octagon Capital Advisors LP now owns 2,830,700 shares of the company’s stock worth $62,360,000 after purchasing an additional 300,000 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new position in Alumis in the fourth quarter valued at $23,443,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.